Using FAPI PET/MRI to Evaluate Prostate Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Wisconsin, Madison
About this trial
The goal of this clinical trial is to gain more information about how FAPI (fibroblast activation protein inhibitor) binds to certain type of cells in the tumor tissue. The main question it aims to answer is how this information can be used to better diagnose and track prostate cancer.
Participants will undergo two PET/MRI scans during two research visits, each of which may last up to 2.5 hours.
Eligibility criteria
Qualifiers
Age 18 years or older
Able and willing to provide informed consent
Known diagnosis of prostate cancer
Scheduled for or recently performed (within 4 weeks) standard-of-care PSMA PET
Disqualifiers
Unable or unwilling to provide informed consent
Contraindication(s) to or inability to undergo PET/MRI
Participants for whom PET/MRI will delay timely delivery of treatment
Have their own prescription for the medication
Trial design
Treatments tested in this trial
- FAPI
- Positron Emission Tomography (PET)
- Magnetic Resonance Imaging
Treatment groups
30 Participants
are divided into 1 treatment groupLocations
1University of Wisconsin53705, MadisonWisconsin, United States
Sponsors and collaborators
University of Wisconsin, Madison
Lead sponsor
Source ClinicalTrials.gov